WO2015130810A3 - Compositions and methods for the treatment of her2/neu over-expressing tumors - Google Patents

Compositions and methods for the treatment of her2/neu over-expressing tumors Download PDF

Info

Publication number
WO2015130810A3
WO2015130810A3 PCT/US2015/017559 US2015017559W WO2015130810A3 WO 2015130810 A3 WO2015130810 A3 WO 2015130810A3 US 2015017559 W US2015017559 W US 2015017559W WO 2015130810 A3 WO2015130810 A3 WO 2015130810A3
Authority
WO
WIPO (PCT)
Prior art keywords
her2
methods
compositions
treatment
expressing tumors
Prior art date
Application number
PCT/US2015/017559
Other languages
French (fr)
Other versions
WO2015130810A2 (en
Inventor
Vafa Shahabi
Anu Wallecha
Paulo C. Maciag
Yvonne Paterson
Nicola Mason
Matthew Seavey
Original Assignee
Advaxis, Inc.
The Trustees Of The University Of Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/189,008 external-priority patent/US20150366955A9/en
Priority claimed from US14/268,436 external-priority patent/US20140234370A1/en
Priority to MX2016011114A priority Critical patent/MX2016011114A/en
Priority to CN201580010568.4A priority patent/CN106661538A/en
Priority to CA2940646A priority patent/CA2940646A1/en
Priority to RU2016137834A priority patent/RU2016137834A/en
Priority to BR112016019534A priority patent/BR112016019534A2/en
Priority to AU2015223136A priority patent/AU2015223136A1/en
Priority to KR1020247007406A priority patent/KR20240038103A/en
Priority to EP15755609.3A priority patent/EP3110942A4/en
Priority to SG11201607036XA priority patent/SG11201607036XA/en
Priority to NZ723750A priority patent/NZ723750A/en
Priority to JP2016553897A priority patent/JP2017507943A/en
Priority to KR1020167025517A priority patent/KR20160122829A/en
Application filed by Advaxis, Inc., The Trustees Of The University Of Pennsylvania filed Critical Advaxis, Inc.
Priority to US15/121,421 priority patent/US20160361401A1/en
Priority to US14/669,629 priority patent/US10016617B2/en
Priority to MX2016014367A priority patent/MX2016014367A/en
Priority to MA039942A priority patent/MA39942A/en
Priority to JP2017509588A priority patent/JP2017514904A/en
Priority to AU2015253737A priority patent/AU2015253737A1/en
Priority to CA2947677A priority patent/CA2947677A1/en
Priority to CN201580036168.0A priority patent/CN106794234A/en
Priority to PCT/US2015/024048 priority patent/WO2015167748A1/en
Priority to EP15786740.9A priority patent/EP3137107A4/en
Priority to KR1020167033949A priority patent/KR20170002552A/en
Priority to SG11201609135VA priority patent/SG11201609135VA/en
Publication of WO2015130810A2 publication Critical patent/WO2015130810A2/en
Publication of WO2015130810A3 publication Critical patent/WO2015130810A3/en
Priority to IL247436A priority patent/IL247436A0/en
Priority to IL248704A priority patent/IL248704A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention provides compositions and methods for treating and vaccinating against a HER2/neu antigen-expressing tumor and inducing an immune response against the same in a subject.
PCT/US2015/017559 2009-11-11 2015-02-25 Compositions and methods for the treatment of her2/neu over-expressing tumors WO2015130810A2 (en)

Priority Applications (26)

Application Number Priority Date Filing Date Title
US15/121,421 US20160361401A1 (en) 2009-11-11 2015-02-25 Compositions and methods for the treatment of her2/neu over-expressing tumors
KR1020247007406A KR20240038103A (en) 2014-02-25 2015-02-25 Compositions and methods for the treatment of her2/neu over-expressing tumors
EP15755609.3A EP3110942A4 (en) 2014-02-25 2015-02-25 Compositions and methods for the treatment of her2/neu over-expressing tumors
CA2940646A CA2940646A1 (en) 2014-02-25 2015-02-25 Compositions and methods for the treatment of her2/neu over-expressing tumors
RU2016137834A RU2016137834A (en) 2014-02-25 2015-02-25 COMPOSITIONS AND METHODS FOR TREATING TUMORS SUPERPRESSING HER2 / neu
BR112016019534A BR112016019534A2 (en) 2014-02-25 2015-02-25 methods of treating tumor growth and eliciting an enhanced immune response against tumor growth
AU2015223136A AU2015223136A1 (en) 2014-02-25 2015-02-25 Compositions and methods for the treatment of HER2/Neu over-expressing tumors
MX2016011114A MX2016011114A (en) 2014-02-25 2015-02-25 Compositions and methods for the treatment of her2/neu over-expressing tumors.
CN201580010568.4A CN106661538A (en) 2014-02-25 2015-02-25 Compositions and methods for the treatment of HER2/NEU over-expressing tumors
SG11201607036XA SG11201607036XA (en) 2014-02-25 2015-02-25 Compositions and methods for the treatment of her2/neu over-expressing tumors
NZ723750A NZ723750A (en) 2014-02-25 2015-02-25 Compositions and methods for the treatment of her2/neu over-expressing tumors
JP2016553897A JP2017507943A (en) 2014-02-25 2015-02-25 Compositions and methods for the treatment of HER2 / NEU overexpressing tumors
KR1020167025517A KR20160122829A (en) 2014-02-25 2015-02-25 Compositions and methods for the treatment of her2/neu over-expressing tumors
US14/669,629 US10016617B2 (en) 2009-11-11 2015-03-26 Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
KR1020167033949A KR20170002552A (en) 2014-05-02 2015-04-02 Combination immuno therapy and radiotherapy for the treatment of her-2-positive cancers
SG11201609135VA SG11201609135VA (en) 2014-05-02 2015-04-02 Combination immuno therapy and radiotherapy for the treatment of her-2-positive cancers
MA039942A MA39942A (en) 2014-05-02 2015-04-02 Combination immuno therapy and radiotherapy for the treatment of her-2-positive cancers
PCT/US2015/024048 WO2015167748A1 (en) 2014-05-02 2015-04-02 Combination immuno therapy and radiotherapy for the treatment of her-2-positive cancers
JP2017509588A JP2017514904A (en) 2014-05-02 2015-04-02 Combined immunotherapy and radiation therapy for the treatment of HER2-positive cancer
AU2015253737A AU2015253737A1 (en) 2014-05-02 2015-04-02 Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
CA2947677A CA2947677A1 (en) 2014-05-02 2015-04-02 Combination immuno therapy and radiotherapy for the treatment of her-2-positive cancers
CN201580036168.0A CN106794234A (en) 2014-05-02 2015-04-02 Combined immunization therapy and radiotherapy for treating the positive cancers of HER 2
MX2016014367A MX2016014367A (en) 2014-05-02 2015-04-02 Combination immuno therapy and radiotherapy for the treatment of her-2-positive cancers.
EP15786740.9A EP3137107A4 (en) 2014-05-02 2015-04-02 Combination immuno therapy and radiotherapy for the treatment of her-2-positive cancers
IL247436A IL247436A0 (en) 2014-02-25 2016-08-23 Compositions and methods for the treatment of her2/neu over-expressing tumors
IL248704A IL248704A0 (en) 2014-05-02 2016-11-02 Combination immuno therapy and radiotherapy for the treatment of her-2-positive cancers

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US14/189,008 2014-02-25
US14/189,008 US20150366955A9 (en) 2009-11-11 2014-02-25 Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
US14/268,436 2014-05-02
US14/268,436 US20140234370A1 (en) 2009-11-11 2014-05-02 Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
US201462076411P 2014-11-06 2014-11-06
US62/076,411 2014-11-06

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US14/268,436 Continuation US20140234370A1 (en) 2008-05-19 2014-05-02 Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/945,386 Continuation-In-Part US9084747B2 (en) 2008-05-19 2010-11-12 Compositions and methods for prevention of escape mutation in the treatment of HER2/NEU over-expressing tumors

Publications (2)

Publication Number Publication Date
WO2015130810A2 WO2015130810A2 (en) 2015-09-03
WO2015130810A3 true WO2015130810A3 (en) 2016-01-28

Family

ID=54009773

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/017559 WO2015130810A2 (en) 2009-11-11 2015-02-25 Compositions and methods for the treatment of her2/neu over-expressing tumors

Country Status (13)

Country Link
EP (1) EP3110942A4 (en)
JP (1) JP2017507943A (en)
KR (2) KR20240038103A (en)
CN (1) CN106661538A (en)
AU (1) AU2015223136A1 (en)
BR (1) BR112016019534A2 (en)
CA (1) CA2940646A1 (en)
IL (1) IL247436A0 (en)
MX (1) MX2016011114A (en)
NZ (1) NZ723750A (en)
RU (1) RU2016137834A (en)
SG (1) SG11201607036XA (en)
WO (1) WO2015130810A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
CA2829960A1 (en) 2011-03-11 2012-09-20 John Rothman Listeria-based adjuvants
AU2013232291B8 (en) 2012-03-12 2016-07-21 Advaxis, Inc. Suppressor cell function inhibition following listeria vaccine treatment
KR20160130774A (en) 2014-02-18 2016-11-14 어드박시스, 인크. Biomarker directed multi-target immunotherapy
SG11201607213QA (en) * 2014-03-05 2016-09-29 Advaxis Inc Methods and compositions for increasing a t-effector cell to regulatory t cell ratio
WO2015164121A1 (en) 2014-04-24 2015-10-29 Advaxis, Inc. Recombinant listeria vaccine strains and methods of producing the same
MA41644A (en) 2015-03-03 2018-01-09 Advaxis Inc LISTERIA-BASED COMPOSITIONS INCLUDING A MINIGEN EXPRESSION SYSTEM CODING PEPTIDES, AND METHODS OF USE THEREOF
KR20180107102A (en) 2015-12-16 2018-10-01 그릿스톤 온콜로지, 인코포레이티드 Identification of new antigens, manufacture, and uses
AU2017367642A1 (en) 2016-11-30 2019-05-30 Advaxis, Inc. Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof
AU2018336988B2 (en) 2017-09-19 2023-06-22 Advaxis, Inc. Compositions and methods for lyophilization of bacteria or Listeria strains
CN111465989A (en) 2017-10-10 2020-07-28 磨石肿瘤生物技术公司 Identification of neoantigens using hot spots
EP3714275A4 (en) 2017-11-22 2021-10-27 Gritstone bio, Inc. Reducing junction epitope presentation for neoantigens

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020025323A1 (en) * 2000-03-29 2002-02-28 Yvonne Paterson Compositions and methods for enhancing immunogenicity of antigens
US20120014984A1 (en) * 2009-11-11 2012-01-19 Vafa Shahabi Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020025323A1 (en) * 2000-03-29 2002-02-28 Yvonne Paterson Compositions and methods for enhancing immunogenicity of antigens
US20120014984A1 (en) * 2009-11-11 2012-01-19 Vafa Shahabi Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors

Also Published As

Publication number Publication date
BR112016019534A2 (en) 2017-10-24
KR20240038103A (en) 2024-03-22
KR20160122829A (en) 2016-10-24
EP3110942A2 (en) 2017-01-04
IL247436A0 (en) 2016-11-30
JP2017507943A (en) 2017-03-23
RU2016137834A (en) 2018-03-29
MX2016011114A (en) 2017-02-20
SG11201607036XA (en) 2016-09-29
WO2015130810A2 (en) 2015-09-03
CA2940646A1 (en) 2015-09-03
AU2015223136A1 (en) 2016-09-22
NZ723750A (en) 2024-02-23
CN106661538A (en) 2017-05-10
EP3110942A4 (en) 2017-08-30

Similar Documents

Publication Publication Date Title
WO2015130810A3 (en) Compositions and methods for the treatment of her2/neu over-expressing tumors
IL265755A (en) Chimeric antigen receptors for the treatment of cancer
EP3538130A4 (en) Immunotherapeutic tumor treatment method
IL260443B (en) Anti-egfr combinations for treating tumors
WO2016070051A3 (en) Combination therapy for treatment of disease
MX2021013837A (en) Combination immunotherapy approach for treatment of cancer.
MX2017004715A (en) Humanized anti-ox40 antibodies and uses thereof.
WO2016191643A3 (en) Tigit-binding agents and uses thereof
WO2016100985A3 (en) Chimeric antigen receptors and methods of use thereof
IL263382A (en) Compositions and methods for tumor vaccination and immunotherapy involving her2/neu
TN2016000559A1 (en) Monoclonal antibodies against her2 epitope and methods of use thereof
IL264674B1 (en) Anti-siglec-7 antibodies for the treatment of cancer
MX2017011246A (en) Listeria-based compositions comprising a peptide minigene expression system and methods of use thereof.
TW201613647A (en) Compounds and compositions for treating HER2 positive tumors
ZA201900960B (en) Methods and compositions for the treatment of cancer
WO2017049038A3 (en) Anti-cd115 antibodies
WO2017040666A3 (en) Combination therapy for treatment of disease
MA39909A (en) Igf-1r antibody-drug-conjugate and its use for the treatment of cancer
IL290130A (en) Treatment of immune evasive tumors
IL263562A (en) Methods and compositions for prostate cancer diagnosis and treatment
EP3628010A4 (en) Immunotherapeutic tumor treatment method
ZA201808232B (en) Compositions and methods for the treatment of cancer
ZA202204223B (en) Vaccination with mica/b alpha 3 domain for the treatment of cancer
WO2015139020A3 (en) Vaccine compositions and methods for restoring nkg2d pathway function against cancers
IL280468A (en) Immune modifying particles for the treatment of cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15755609

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 247436

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2016553897

Country of ref document: JP

Kind code of ref document: A

Ref document number: 2940646

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 15121421

Country of ref document: US

Ref document number: MX/A/2016/011114

Country of ref document: MX

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112016019534

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20167025517

Country of ref document: KR

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2015755609

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015755609

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2015223136

Country of ref document: AU

Date of ref document: 20150225

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2016137834

Country of ref document: RU

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15755609

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 112016019534

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20160824